July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Evaluation of iPS-derived retinal pigment epithelium (iRPE) as a model for in vitro lentiviral-based gene therapy
Author Affiliations & Notes
  • Florian Udry
    Jules Gonin Eye Hospital, Université de Lausanne, Lausanne, Vaud, Switzerland
  • Sarah Decembrini
    Jules Gonin Eye Hospital, Université de Lausanne, Lausanne, Vaud, Switzerland
  • Corinne Kostic
    Jules Gonin Eye Hospital, Université de Lausanne, Lausanne, Vaud, Switzerland
  • David M Gamm
    Ophtalmology and Visual Science, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Yvan Arsenijevic
    Jules Gonin Eye Hospital, Université de Lausanne, Lausanne, Vaud, Switzerland
  • Footnotes
    Commercial Relationships   Florian Udry, None; Sarah Decembrini, None; Corinne Kostic, None; David Gamm, None; Yvan Arsenijevic, None
  • Footnotes
    Support  SwissTransmed and SNF
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4583. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Florian Udry, Sarah Decembrini, Corinne Kostic, David M Gamm, Yvan Arsenijevic; Evaluation of iPS-derived retinal pigment epithelium (iRPE) as a model for in vitro lentiviral-based gene therapy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4583.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Deficiencies in functions RPE give rise to several diseases, of which most of them result in visual impairments or blindness. The generation of hRPE for disease modelling is particularly worth to answer these major challenges. Here, we evaluate the suitability of iRPE as an in vitro model for lentiviral (LV) gene therapy (GT).

Methods : Human iPSCs were differentiated to iRPE using a protocol derived from Singh et al. (2013). All iRPE and foetal RPE (fRPE, Lonza) were P3 and matured 42 days on Transwell. hiPSCs, fRPE and iRPE mRNA expression was quantified by qPCR and analyzed by one-way ANOVA. Transepithelial resistance (TER) and growth factor secretion (by ELISA) were measured on iRPE cultures respectively and analyzed by Wilcoxon Signed Rank Test. iRPE and fRPE were transduced with different GFP constructs and FACSed 5 days later, DNA extracted, LTR sequence integration was quantified by qPCR and linear regressions were performed between the proportion of GFP+ cells and LTR-to-β-ACTIN ratio. All results are written as Mean±SD.

Results : RPE mRNA markers were upregulated in iRPE compared to hiPSCs such as RPE65, MITF-H, PMEL-17, DCT, BEST1. Immunostaining assessed the presence of RPE65, CRALBP, OTX2 proteins and ZO-1 apical and BEST1 basolateral localization. Electron microscopy revealed apical microvilli, melanosomes and tight-junctions. TER values showed a consistent resistance of iRPE above 200Ω*cm2 from day 28 onwards (305.7±97.26Ω*cm2, Pv: <0.001). PEDF and VEGF secretion range was consistent with literature but not significantly polarized (apical vs basal ng/24h/cm2: 407.6±74.1 vs 453.6±120.3, Pv: 0.43, 8.1±2.8 vs 19.7±7.7, Pv: 0.06, respectively). Phagocytosis assay confirmed iRPE cells phagocytic ability. To test iRPE and fRPE cells reaction to LV GT, transduction of GFP constructs driven by different promoters was performed. Only EFS and R0.8 promoters showed a positive correlation between LV integration and GFP+ cells compared to GFAP, RHODOPSIN, SYNAPSIN and rNse which drive no reporter gene expression. In addition we performed a gene dosing test for RPE65 expression and observed a 3 fold RPE65 increase using LV.

Conclusions : In conclusion, iRPE revealed to be a suitable in vitro model to test GT constructs.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×